华东医药：关于控股子公司获得药物临床试验批准通知书的公告

Core Viewpoint - The announcement indicates that East China Pharmaceutical's subsidiary, Zhejiang Daor Biotechnology Co., Ltd., has received FDA approval for clinical trials of the drug DR10624 in the United States [2] Group 1 - East China Pharmaceutical's subsidiary, Daor Biotechnology, has successfully submitted a clinical trial application for the drug DR10624 [2] - The FDA's approval allows Daor Biotechnology to conduct clinical trials in the U.S. market [2]